Cutaneous toxicity following intra-arterial chemotherapy with melphalan for uveal melanoma: A case report

IF 0.2 Q4 ONCOLOGY
Arthur Sampaio Zupelli , Victor C.F. Bellanda , Daniel G. Abud , Gabriela M. Carvalho , Luiz Augusto F.M. Garbers , Fernanda M. Peria , Rodrigo Jorge
{"title":"Cutaneous toxicity following intra-arterial chemotherapy with melphalan for uveal melanoma: A case report","authors":"Arthur Sampaio Zupelli ,&nbsp;Victor C.F. Bellanda ,&nbsp;Daniel G. Abud ,&nbsp;Gabriela M. Carvalho ,&nbsp;Luiz Augusto F.M. Garbers ,&nbsp;Fernanda M. Peria ,&nbsp;Rodrigo Jorge","doi":"10.1016/j.cpccr.2024.100318","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>This case report aims to describe an adverse reaction following intra-arterial melphalan chemotherapy in a 48-year-old female patient with choroidal melanoma. The chemotherapy was part of a phase I clinical trial (MELCOM Study - ClinicalTrials.gov ID: NCT05893654), designed to evaluate its efficacy as a bridge to Ru-106 brachytherapy for treating large uveal melanomas. This is the first reported case of a cutaneous reaction to melphalan in an adult patient.</p></div><div><h3>Observations</h3><p>Upon administration of melphalan, the patient developed an erythematous periorbital skin lesion three days post-treatment. The lesion evolved into a hyperchromic brownish macule that later disappeared spontaneously.</p></div><div><h3>Conclusions and Importance</h3><p>While melphalan successfully reduced the tumor dimensions, making the patient eligible for subsequent Ru-106 brachytherapy, it led to a cutaneous reaction previously reported only in pediatric patients. Despite this aesthetic complication, the therapy was effective in tumor reduction, highlighting the need for further studies to assess the risk-benefit profile of intra-arterial melphalan chemotherapy in adult populations.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.2000,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621924000413/pdfft?md5=c96c3df08b57baf46f2ebade3beca62b&pid=1-s2.0-S2666621924000413-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current problems in cancer. Case reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666621924000413","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

This case report aims to describe an adverse reaction following intra-arterial melphalan chemotherapy in a 48-year-old female patient with choroidal melanoma. The chemotherapy was part of a phase I clinical trial (MELCOM Study - ClinicalTrials.gov ID: NCT05893654), designed to evaluate its efficacy as a bridge to Ru-106 brachytherapy for treating large uveal melanomas. This is the first reported case of a cutaneous reaction to melphalan in an adult patient.

Observations

Upon administration of melphalan, the patient developed an erythematous periorbital skin lesion three days post-treatment. The lesion evolved into a hyperchromic brownish macule that later disappeared spontaneously.

Conclusions and Importance

While melphalan successfully reduced the tumor dimensions, making the patient eligible for subsequent Ru-106 brachytherapy, it led to a cutaneous reaction previously reported only in pediatric patients. Despite this aesthetic complication, the therapy was effective in tumor reduction, highlighting the need for further studies to assess the risk-benefit profile of intra-arterial melphalan chemotherapy in adult populations.

葡萄膜黑色素瘤动脉内美法仑化疗后的皮肤毒性:病例报告
背景本病例报告旨在描述一名48岁的脉络膜黑色素瘤女性患者在接受美法仑动脉内化疗后出现的不良反应。化疗是I期临床试验(MELCOM研究--ClinicalTrials.gov ID:NCT05893654)的一部分,旨在评估其作为Ru-106近距离放射治疗大面积葡萄膜黑色素瘤的桥梁的疗效。观察结果患者在接受美法仑治疗三天后,眶周皮肤出现红斑。结论和重要性虽然美法仑成功缩小了肿瘤尺寸,使患者有资格接受随后的 Ru-106 近距离放射治疗,但却导致了之前仅在儿童患者中报道过的皮肤反应。尽管出现了这种影响美观的并发症,但该疗法还是有效地缩小了肿瘤,因此有必要开展进一步研究,以评估成年患者接受动脉内美法仑化疗的风险收益情况。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.40
自引率
0.00%
发文量
0
审稿时长
96 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信